American Association for Cancer Research (AACR) annual meeting 2014,
abstract 831; Cancer Research 2014, 74 (19 supplement)
12. A. Schmitt-Hoffmann, D. Klauer, K. Gebhardt et al. BAL27862: a unique
microtubule-targeted agent with a potential for the treatment of human
brain tumors. AACR-NCI-EORTC conference 2009, abstract C233; Molecular
Cancer Therapeutics 2009, 8 (12 supplement)
13. A. C. Mladek, J. L. Pokorny, H. Lane et al. The novel tubulin-binding
'tumor checkpoint controller' BAL101553 has anti-cancer activity alone
and in combination treatments across a panel of GBM patient-derived
xenografts. American Association for Cancer Research (AACR) annual
meeting 2016, abstract 4781; Cancer Research 2016, 76 (14 supplement)
14. A. E. Prota, F. Danel, F. Bachmann et al. The novel
microtubule-destabilizing drug BAL27862 binds to the colchicine site of
tubulin with distinct effects on microtubule organization. Journal of
Molecular Biology 2014 (426), 1848-1860
15. F. Bachmann, K. Burger, H. Lane. BAL101553 (prodrug of BAL27862): the
spindle assembly checkpoint is required for anticancer activity. American
Association for Cancer Research (AACR) annual meeting 2015, abstract
3789; Cancer Research 2015, 75 (15 supplement)
Attachment
-- Press release (PDF)
https://ml-eu.globenewswire.com/Resource/Download/3d59bbce-df2e-4ee6-89cb-e63c96206706
(END) Dow Jones Newswires
June 07, 2021 01:15 ET (05:15 GMT)